- Trials with a EudraCT protocol (703)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
703 result(s) found for: Body growth.
Displaying page 1 of 36.
EudraCT Number: 2013-003100-39 | Sponsor Protocol Number: NSGA | Start Date*: 2013-11-28 | |||||||||||
Sponsor Name:Dutch Growth Research Foundation | |||||||||||||
Full Title: Standardized versus individualized growth hormone treatment of short children born small for gestational age: Effects on short-term and longterm efficacy, long-term psychosocial development, gluc... | |||||||||||||
Medical condition: Children who are born small for gestational age, defined as a birth length and/or birth weight < -2 SD score, who fail to show catch-up growth (short stature). | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-005398-32 | Sponsor Protocol Number: STRIDER | Start Date*: 2014-07-18 | |||||||||||
Sponsor Name:Liverpool Women's NHSFT [...] | |||||||||||||
Full Title: A randomised controlled trial of sildenafil therapy in dismal prognosis early-onset intrauterine growth restriction | |||||||||||||
Medical condition: Early onset intrauterine growth restriction | |||||||||||||
|
|||||||||||||
Population Age: | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-002991-40 | Sponsor Protocol Number: A6281269 | Start Date*: 2015-04-01 |
Sponsor Name:Pfizer Inc | ||
Full Title: Evolution of Growth Rate in Children Suffering From a Disease Associated With Growth Retardation and Treated by Genotonorm. A Pilot Study | ||
Medical condition: Growth Disorders, Growth Retardation | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2014-004525-41 | Sponsor Protocol Number: 14VR4 | Start Date*: 2015-04-10 | |||||||||||
Sponsor Name:Versartis, Inc. | |||||||||||||
Full Title: Comparison of Somavaratan (VRS-317), a Long-acting Human Growth Hormone, to Daily rhGH in a Phase 3, Randomized, One-year, Open-label, Multi-center, Non-inferiority Trial in Pre-pubertal Children w... | |||||||||||||
Medical condition: Growth hormone deficiency | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) BE (Completed) NL (Ongoing) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-005593-79 | Sponsor Protocol Number: A6391004 | Start Date*: 2006-06-02 | |||||||||||
Sponsor Name:Pfizer Limited | |||||||||||||
Full Title: A Double blind, third party open, single dose study to explore the safety, pharmacokinetics and pharmacodynamics of pha-794428 in paediatric patients with growth hormone deficiency | |||||||||||||
Medical condition: Paediatric Growth Hormone Deficiency | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) ES (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-008240-25 | Sponsor Protocol Number: NN8630-1824 | Start Date*: 2009-09-02 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: A randomised, open-labelled, single dose, dose-escalation trial investigating safety, tolerability, pharmacokinetics and pharmacodynamics of pegylated long-acting human growth hormone (NNC126-0083)... | |||||||||||||
Medical condition: growth hormone deficiency (GHD) in children | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) BE (Completed) SI (Completed) GB (Completed) ES (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-001313-14 | Sponsor Protocol Number: 2007-189-2 | Start Date*: 2012-10-17 | |||||||||||
Sponsor Name:Dutch growth research foundation | |||||||||||||
Full Title: Young adult Prader-Willi Study Effects of Growth Hormone after final height: A clinical care study to the optimal dosage of growth hormone in young adults with PWS. | |||||||||||||
Medical condition: Prader Willi Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001826-61 | Sponsor Protocol Number: 11‐HM10560A‐201 | Start Date*: 2011-07-29 | |||||||||||
Sponsor Name:Hanmi Pharmaceutical Co., Ltd. | |||||||||||||
Full Title: A phase II, randomized, active controlled, open label study of safety and efficacy of HM10560A a Long-acting rhGH-HMC001 conjugate in treatment of subjects suffering from adult growth hormone defic... | |||||||||||||
Medical condition: Adult growth hormone deficiency (AGHD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) PL (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-000013-20 | Sponsor Protocol Number: NN8640-4042 | Start Date*: 2013-12-09 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: A randomised, open-labelled, active-controlled, multinational, dose-escalation trial investigating safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of long-acting growth... | |||||||||||||
Medical condition: Growth hormone deficiency in children | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: SI (Completed) BE (Completed) AT (Completed) SE (Completed) ES (Completed) FR (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-011534-10 | Sponsor Protocol Number: 7798 | Start Date*: 2009-06-23 |
Sponsor Name:Karolinska University Hospital | ||
Full Title: Effects on insulin sensitivity and body composition of combination therapy with growth hormone (GH) and insulin-like growth factor-I (IGF-I) in growth hormone deficient adults with impaired glucose... | ||
Medical condition: To evaluate the effect on glucose sensitivity and body composition of combination therapy with GH and IGF-I in growth hormone deficient adults with impaired glucose tolerance or diabetes. The hypot... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-002992-17 | Sponsor Protocol Number: A6281271 | Start Date*: 2015-05-14 | |||||||||||
Sponsor Name:Pfizer, Inc. | |||||||||||||
Full Title: EVOLUTION OF GROWTH RATE IN CHILDREN WITH GROWTH RETARDATION RELATED TO LONG-TERM GLUCOCORTICOSTEROID THERAPY AND TREATED BY GENOTONORM® | |||||||||||||
Medical condition: Growth retardation related to long-term glucocorticoid therapy | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-002507-32 | Sponsor Protocol Number: IBD8 | Start Date*: 2004-10-11 |
Sponsor Name:Royal Hospital For Sick Children, Yorkhill Division | ||
Full Title: Effect of recombinant growth hormone on growth and chondrocyte dynamics in children with Inflammatory bowel disease (IBD) and growth failure. | ||
Medical condition: Growth retardation secondary to inflammatory bowel disease in children | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-004153-25 | Sponsor Protocol Number: JIA6 | Start Date*: 2004-12-10 |
Sponsor Name:Royal Hospital For Sick Children, Yorkhill Division | ||
Full Title: Effect of recombinant growth hormone on growth and chondrocyte dynamics in children with juvenile idiopathic arthritis (JIA) and growth failure. | ||
Medical condition: Growth retardation secondary to juvenile idiopathic arthritis | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2013-002892-16 | Sponsor Protocol Number: NN8640-4054 | Start Date*: 2014-10-07 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: A multicentre, multinational, randomised, parallel-group, placebo-controlled (double blind) and active-controlled (open) trial to compare the efficacy and safety of once weekly dosing of NNC0195-00... | |||||||||||||
Medical condition: Growth hormone deficiency in adults | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) GB (Completed) DE (Completed) LT (Completed) LV (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001020-36 | Sponsor Protocol Number: MS301 | Start Date*: 2019-05-31 |
Sponsor Name:Ipsen Pharma | ||
Full Title: RECOMBINANT HUMAN INSULIN-LIKE GROWTH FACTOR-1 (rhIGF-1) TREATMENT OF PREPUBERTAL CHILDREN WITH GROWTH FAILURE ASSOCIATED WITH PRIMARY IGF-1 DEFICIENCY: A PHASE 3, RANDOMIZED, OPEN LABEL, OBSERVATI... | ||
Medical condition: Children with growth failure associated with primary insulin-like growth factor deficiency (IGFD). | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2015-001681-25 | Sponsor Protocol Number: 23681 | Start Date*: 2015-07-15 |
Sponsor Name:Merck KGaA | ||
Full Title: An Open, Multicenter, Randomized, Controlled Trial to Evaluate the Correlation Between Spontaneous Catch-up Growth, Clinical Response to Saizen (Recombinant Human Growth Hormone, r-hGH) and Gene Ex... | ||
Medical condition: Small for Gestational Age | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2008-001674-32 | Sponsor Protocol Number: NordiNet-IOS | Start Date*: 2009-04-29 | |||||||||||
Sponsor Name:Novo Nordisk Farma Oy | |||||||||||||
Full Title: NordiNet International Outcome Study (NordiNet IOS) | |||||||||||||
Medical condition: Small Gestation Age, Turner Syndrome, Growth Hormone Deficiency | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-002736-13 | Sponsor Protocol Number: TV1106-IMM-30022 | Start Date*: 2015-08-19 | |||||||||||
Sponsor Name:Teva Pharmaceutical Industries Ltd. | |||||||||||||
Full Title: A phase 3, multicenter, randomized, open-label, comparator-controlled study to assess safety and tolerability of weekly TV-1106 compared to daily rhGH (Genotropin®) in adults with growth hormone-de... | |||||||||||||
Medical condition: Growth hormone deficiency | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) HU (Completed) SE (Prematurely Ended) IT (Prematurely Ended) AT (Completed) ES (Prematurely Ended) SI (Prematurely Ended) LT (Prematurely Ended) GR (Prematurely Ended) CZ (Prematurely Ended) PL (Prematurely Ended) SK (Prematurely Ended) HR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-004313-39 | Sponsor Protocol Number: TCH-306EXT | Start Date*: 2022-06-17 | |||||||||||
Sponsor Name:Ascendis Pharma Endocrinology Division A/S | |||||||||||||
Full Title: A Multicenter, Open-Label, Extension Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults with Growth Hormone Deficiency | |||||||||||||
Medical condition: Adult Growth Hormone Deficiency (AGHD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Completed) SK (Completed) FR (Completed) ES (Ongoing) DE (Completed) IT (Completed) RO (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000647-14 | Sponsor Protocol Number: 15782601 | Start Date*: 2016-05-23 |
Sponsor Name:University Hospital Toulouse | ||
Full Title: Treatment with HMG-COA reductase inhibitor (simvastatin) of growth and bone abnormalities in children with Noonan syndrome : a phase III randomised, double-blind, placebo-controlled therapeutic trial | ||
Medical condition: Noonan syndrome | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
